Please login to the form below
Dupixent
This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.
FDA approves Sanofi’s key cancer drug Sarclisa for myeloma
That included its blockbuster immunology treatment Dupixent (dupilumab), its vaccine business and a robust pipeline littered with potential candidates for rare disease, multiple sclerosis and breast and lung cancer.
Latest news
-
Incyte’s JAK inhibitor cream clears second eczema trial
So if approved, ruxolitinib cream would address a less severely-affected population than new biologic agents such as Sanofi/Regeneron’s blockbuster Dupixent (dupilumab) antibody.
-
Sanofi highlights MS drug data as it swings to a loss in Q4
The new MS data comes as Sanofi swung to a small, 10m net loss in the fourth quarter of 2019, despite another strong performance by immunology drug Dupixent (dupilumab) which grew ... Dupixent plus solid growth for Sanofi’s vaccines business lifted
-
Lilly expands dermatology portfolio with $1.1bn Dermira deal
If approved, Lilly’s newly acquired drug will closely compete with Sanofi/Regenerons’s Dupixent (dupilumab) which grew 142% in the last quarter to $637m.
-
Almirall eyes $62m takeover of multicytokine specialist Bioniz
If approved, that would be a rival to Sanofi and Regeneron’s fast-growing atopic dermatitis therapy Dupixent (dupilumab).
-
Sanofi narrows focus, shedding diabetes and cardiovascular research
This includes focusing on the growth of its immunology drug Dupixent (dupilumab), which increased in sales by 142% in the third quarter of this year to an impressive 570m ($637m). ... However, in its strategy update, Sanofi has aimed even higher, with
More from news
Approximately 21 fully matching, plus 30 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma leaders to watch in 2020
Dupixent for eczema and asthma – in order to ramp up internal generation of new drug candidates.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Moderna completes enrolment of phase 3 COVID-19 vaccine trial
- Novartis’ MS therapy Mayzent approved by NICE
- GSK chief exec ‘optimistic’ COVID-19 vaccine could be available next year
- The Truth about Doctors
- How will the events and exhibitions industry change post-Coronavirus?
- Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses
- Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
- Lilly’s Q3 earnings slump on COVID-19 development costs, pricing pressures
- Keytruda growth helps Merck to offset COVID-19 impact in Q3
- Celebrating the hard work and dedication of our wonderful Talent Manager
- The other side of … rheumatoid arthritis
- How to lessen site burden with a targeted patient recruitment strategy
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- The other side of … rheumatoid arthritis
- For Georgie, patient activation fuelled her motivation to find life without pain. So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed......
- How to lessen site burden with a targeted patient recruitment strategy
- Picture this: you’ve created your patient recruitment strategy and you find more and more patients are undertaking the pre-screening, you probably think – success! But then you find out, getting...
- Exploring the potential of eosinophils
- GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
Quick links
Infographics
